Skip to main content
. Author manuscript; available in PMC: 2023 Apr 14.
Published in final edited form as: Immunohorizons. 2022 Dec 1;6(12):872–882. doi: 10.4049/immunohorizons.2100112

Figure 3: Active histone modifications are observed post IL-6 treatment at the Pdcd1 locus.

Figure 3:

(A) Schematic of the Pdcd1 locus illustrating the assayed regions used in histone ChIP experiments, including a negative control sequence within the Pdcd1 gene body. (B-C) Primary splenic CD8 T cells were stimulated with anti-CD3/CD28 beads ex vivo and treated with or without IL-6. Cells were harvested after 1 or 5 days and ChIP was performed using antibodies against (B) active histone modifications H3K9ac, H3K27ac, and H3K4me3, and (C) repressive histone marks H3K27me3 and H3K9me3, with IgG enrichment serving as a negative control. Bar color corresponds to the locations within the Pdcd1 locus defined in (A). Data are represented of three independent experiments and plotted ± SEM. Statistical significance was determined by two-way ANOVA: *, p < 0.05, **; p < 0.01; or ***, p < 0.001.